# Ohio THC Drink Ban Draws Lawsuit from Cincinnati Breweries > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/ohio-thc-beverage-ban-lawsuit/ > **Published:** 2026-03-17T14:46:20-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:05:57-04:00 > **Clinical Summary:** Explore the Ohio THC beverage ban lawsuit and its impact on cannabis product regulations and Cincinnati breweries' legal challenge. --- ✦ New CED Clinical Relevance #92 Landmark Clinical Evidence Peer-reviewed human research with direct implications for [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) practice. THCPolicyIndustry Clinical Summary Ohio’s recent ban on THC-infused beverages has prompted legal challenges from Cincinnati-based breweries, raising questions about the state’s regulatory approach to cannabis products. The breweries argue that the prohibition restricts their ability to produce and sell a growing category of cannabis products that patients and consumers increasingly prefer as an alternative to smoking or traditional edibles. This regulatory action reflects ongoing tension between state-level cannabis policies and the commercial cannabis industry, with implications for product diversity and [patient access](https://cedclinic.com/iowa-medical-cannabis-dispensaries-expansion/) to different delivery methods. From a clinical perspective, THC beverages offer potential advantages for dose control and consistency compared to other formats, though they also present challenges in terms of onset time and abuse potential that regulators may be attempting to address. The outcome of this lawsuit could significantly shape the landscape of available cannabis products in Ohio and potentially influence how other states approach regulation of cannabis-infused beverages. Clinicians should monitor their state’s regulatory decisions regarding cannabis product categories, as restrictions on certain delivery methods may limit treatment options and force patients toward less preferred alternatives. Clinical Perspective ⚖️ The legal challenge to Ohio’s THC beverage ban highlights the growing tension between state regulatory frameworks and cannabis industry expansion, with implications for how healthcare providers counsel patients on product safety and standardization. As THC-infused beverages become more widely available through litigation and regulatory gaps, clinicians should recognize that drinks present particular risks compared to traditional cannabis products, including difficulty controlling dose, delayed onset of effects that may encourage overconsumption, and potential for accidental ingestion by minors or unaware consumers. The regulatory uncertainty surrounding these products means that patients may be purchasing items lacking standardized labeling, potency verification, or safety testing, complicating risk assessment in clinical settings. Healthcare providers should remain informed about their state’s cannabis regulations and be prepared to discuss with patients the potential harms of unregulated THC beverages, including cardiovascular effects and [cannabis hyperemesis syndrome](https://cedclinic.com/remediated-cannabis-mold-contamination-risks/), while advocating for consistent dosing standards and child-resistant 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-related-research/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Ohio+%3Cb%3ETHC%3C%2Fb%3E+drink+ban+draws+lawsuit+from+Cincinnati+breweries+%40drcaplan&url=https%3A%2F%2Fwww.cincinnati.com%2Fstory%2Fnews%2Fpolitics%2F2026%2F03%2F06%2Fohio-thc-drink-ban-draws-lawsuit-from-cincinnati-breweries%2F89020164007%2F)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.cincinnati.com%2Fstory%2Fnews%2Fpolitics%2F2026%2F03%2F06%2Fohio-thc-drink-ban-draws-lawsuit-from-cincinnati-breweries%2F89020164007%2F)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Ohio+%3Cb%3ETHC%3C%2Fb%3E+drink+ban+draws+lawsuit+from+Cincinnati+breweries+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.cincinnati.com%2Fstory%2Fnews%2Fpolitics%2F2026%2F03%2F06%2Fohio-thc-drink-ban-draws-lawsuit-from-cincinnati-breweries%2F89020164007%2F)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) Related Articles - [CED Digest: 230 Items — March 15, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-clinical-relevance-2026/) - [CED Digest: 436 Items — March 14, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) - [CED Digest: 405 Items — March 12, 2026](https://cedclinic.com/alabama-medical-cannabis-sales-2026-spring-launch/) 📰 Source: [https://www.cincinnati.com/story/news/politics/2026/03/06/ohio-thc-drink-ban-draws-lawsuit-from-cincinnati-breweries/89020164007/](https://www.cincinnati.com/story/news/politics/2026/03/06/ohio-thc-drink-ban-draws-lawsuit-from-cincinnati-breweries/89020164007/) Further Reading CED Clinic Blog[Cannabis-Infused Beverages as Alcohol Alternatives: New York at Five Years](https://cedclinic.com/cannabis-beverage-substitution-alcohol-new-york-five-years/) Research Digest[AM Policy Update: March 17, 2026](https://cedclinic.com/dea-synthetic-opioids-schedule-i-march-17-2026/) Cannabis Policy Wire[Schedules of Controlled Substances: Temporary Placement of N-pyrrolidino metonitazene and N-pyrrolidino protonitazene in Schedule I](https://cedclinic.com/nitazene-synthetic-opioids-temporary-schedule-i-placement/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence 2 Greater Cincinnati breweries file lawsuit over Ohio ban on THC beverages – WLWT Detailed coverage of the Cincinnati breweries' legal action challenging Ohio's ban on THC-infused drinks. Read the lawsuit details [Ohio breweries push to overturn DeWine's THC drink ban – 13ABC](https://cedclinic.com/ohio-cannabis-beverage-regulation-thc-drink-ban/) Insights into efforts by Ohio breweries to reverse the state's THC beverage restrictions. [Explore brewery advocacy](https://cedclinic.com/ohio-cannabis-beverage-regulation-thc-drink-ban/) THC-infused drinks face new restrictions in Ohio – NBC4 WCMH-TV An overview of the regulatory changes affecting THC-infused beverages in Ohio. Learn about new restrictions ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).